Osteoporosis Treatment Maker Raises $91M in Reverse Merger Transaction
Posted by admin on May 24, 2011
Radius Health, a Boston-based biotech company focused on women's health, has gone public through a …
Source >>>
Commonwealth Biotechnologies Files Chapter 11
Posted by The Distressed Debt Report on January 21, 2011
Commonwealth Biotechnologies, a Richmond, Va., biotech company, filed Chapter 11 as it plans to dive…
Source >>>
Genzyme rejects Sanofi offer as long battle looms
Posted by Reuters: Business News on August 30, 2010
PARIS/BOSTON (Reuters) – Biotech company Genzyme Inc rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis SA on Monday, setting the stage for a protracted and potentially hostile takeover battle.
Genzyme rejects Sanofi offer, long battle looms
Posted by Reuters: Business News on
PARIS/BOSTON (Reuters) – U.S. biotech company Genzyme Inc rejected an $18.5 billion buyout offer from French drugmaker Sanofi-Aventis SA on Monday, setting the stage for a protracted and potentially hostile takeover battle.
Sanofi-Aventis makes $18.5 billion offer for Genzyme
Posted by Reuters: Business News on August 29, 2010
PARIS (Reuters) – French drugmaker Sanofi-Aventis has submitted a non-binding proposal to acquire U.S. biotech company Genzyme in an all-cash deal worth about $18.5 billion, it said on Sunday.
Sanofi’s Genzyme bid expected in days: source
Posted by Reuters: Business News on July 29, 2010
PHILADELPHIA/PARIS (Reuters) – France’s Sanofi-Aventis is expected to bid up to $18.7 billion for Genzyme Corp by the weekend, but an offer at that price is not likely to sway the U.S. biotech company, sources said on Thursday.
